MedTrace Logo

A Pilot Study of High-Dose, Intravenous Ascorbic Acid (Vitamin C) to Treat Hepatitis C

NCT01250743 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2011-02-18

No results posted yet for this study

Summary

The purpose of this pilot study is to learn whether high doses of ascorbic acid (vitamin c), given intravenously to patients with chronic hepatitis due to infection with the genotype 1 version of the hepatitis C virus, are safe, well-tolerated and able to reduce the amount of virus circulating in the patients' blood.

Conditions

  • Hepatitis C

Interventions

DIETARY_SUPPLEMENT

ascorbic acid (vitamin C)

intravenous vitamin C, 25 to 100 grams, once or twice a week, for five months

Sponsors & Collaborators

  • Health Innovations, Frontier Research Institute

    lead OTHER

Principal Investigators

  • Jeanne A Drisko, MD · University of Kansas Medical Center

  • Michael A Catalano, MD · Frontier Research Institute/Health Innovations

  • Terry A Grossman, MD · Frontier Research Institute/Health Innovations

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-12-31
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01250743 on ClinicalTrials.gov